Li Wei, Venkataraman Gopalakrishnan M, Ain Kenneth B
Thyroid Cancer Research Laboratory, Medical Service, Veterans Affairs Medical Center, Lexington, Kentucky 40511, USA.
J Clin Endocrinol Metab. 2007 Mar;92(3):1080-7. doi: 10.1210/jc.2006-2106. Epub 2006 Dec 12.
Therapy of thyroid carcinoma uses its radioiodine concentration ability for treatment. Dedifferentiated cells lose radioiodine uptake from human sodium-iodide symporter (hNIS) gene transcription failure consequent to genomic structure (chromatin compaction) and composition (CpG methylation).
We explored restoring hNIS expression in human thyroid carcinoma cells using thyroid adenoma and carcinoma cell lines: KAK-1, NPA87, BHT-101, and KAT-4B, with quantitative RT-PCR, chromatin immunoprecipitation, deoxyribonuclease I sensitivity assays, and luciferase reporter construct transfections containing hNIS promoter regions.
Combined 5-azacytidine and sodium butyrate restores hNIS gene transcription in KAK-1 to levels approaching radioiodine-treatable tumors. Despite induction of H4 acetylation, there was no deoxyribonuclease I sensitivity enhancement in two regions of the hNIS gene promoter. Cycloheximide in cells transfected with luciferase reporter construct, 1.3 kb hNIS gene promoter, stimulated normalized luciferase expression, singly and synergistically with 5-azacytidine, in a dose-dependent, time course-dependent, cell type-specific, and promoter-specific fashion. Both anisomycin and emetine, but not puromycin, had similar effects. Cycloheximide also increased endogenous hNIS mRNA. Transfections with reporter constructs containing consecutive deletions of hNIS gene promoter sequences revealed responsible sequences at -427 to -131 bp. Deletion of 1.2 kb promoter region upstream of -131 bp enhanced basal luciferase reporter activity 3-fold above the activity of full length promoter construct, supporting inhibitory properties of this region.
This suggests that trans-active protein factor(s) represses endogenous hNIS transcription in KAK-1 cells under basal conditions, accounting for loss of iodine uptake. Inhibition of this repressive activity increases endogenous hNIS transcription and presents a novel target to restore hNIS expression in dedifferentiated thyroid carcinoma.
甲状腺癌的治疗利用其摄取放射性碘的能力进行治疗。去分化细胞由于基因组结构(染色质压缩)和组成(CpG甲基化)导致人钠-碘同向转运体(hNIS)基因转录失败,从而失去放射性碘摄取能力。
我们利用甲状腺腺瘤和癌细胞系KAK-1、NPA87、BHT-101和KAT-4B,通过定量逆转录聚合酶链反应、染色质免疫沉淀、脱氧核糖核酸酶I敏感性分析以及含有hNIS启动子区域的荧光素酶报告基因构建体转染,探索恢复人甲状腺癌细胞中hNIS的表达。
联合使用5-氮杂胞苷和丁酸钠可将KAK-1细胞中的hNIS基因转录恢复到接近可进行放射性碘治疗的肿瘤水平。尽管诱导了H4乙酰化,但hNIS基因启动子的两个区域中脱氧核糖核酸酶I敏感性并未增强。在转染了荧光素酶报告基因构建体(1.3 kb hNIS基因启动子)的细胞中,环己酰亚胺以剂量依赖性、时间进程依赖性、细胞类型特异性和启动子特异性方式单独或与5-氮杂胞苷协同刺激荧光素酶表达正常化。茴香霉素和依米丁(而非嘌呤霉素)也有类似作用。环己酰亚胺还增加了内源性hNIS mRNA。用含有hNIS基因启动子序列连续缺失的报告基因构建体转染后发现,-427至-131 bp处存在相关序列。缺失-131 bp上游1.2 kb启动子区域可使基础荧光素酶报告基因活性比全长启动子构建体的活性提高3倍,这支持了该区域的抑制特性。
这表明在基础条件下,反式激活蛋白因子抑制KAK-1细胞中的内源性hNIS转录,这是碘摄取丧失的原因。抑制这种抑制活性可增加内源性hNIS转录,并为恢复去分化甲状腺癌中hNIS的表达提供了一个新靶点。